financetom
Business
financetom
/
Business
/
Informatica Says Cloud Data Management Company Not Engaged in Acquisition Talks; Shares Tumble
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Informatica Says Cloud Data Management Company Not Engaged in Acquisition Talks; Shares Tumble
Apr 22, 2024 11:01 AM

01:30 PM EDT, 04/22/2024 (MT Newswires) -- Informatica ( INFA ) said Monday it is not in talks to be acquired, refuting a recent report by The Wall Street Journal, sending the cloud data management company's shares tumbling.

On April 12, the Journal reported that Salesforce ( CRM ) was in late-stage discussions to acquire Informatica ( INFA ), according to people familiar with the matter. "Although Informatica's ( INFA ) policy is not to comment on market rumors or media speculation, the company announced that it is not currently engaged in any discussions to be acquired," Informatica ( INFA ) said Monday.

The WSJ separately reported late Sunday that the discussions between Informatica ( INFA ) and Salesforce ( CRM ) had ended after the companies failed to agree on the terms of a potential deal.

Informatica ( INFA ) shares were down 8.9% in Monday afternoon trade, while Salesforce ( CRM ) rose 1.1%. Salesforce ( CRM ) didn't respond to MT Newswires' request for comment on the latest WSJ report.

Informatica ( INFA ) said Monday it expects first-quarter revenue and non-GAAP operating income to be within the upper half of its previously outlined guidance ranges. It projects subscription annual recurring revenue and cloud subscription ARR to also fall in the top half of the prior ranges.

In February, the company projected first-quarter revenue at $375 million to $395 million and subscription ARR between $1.14 billion and $1.16 billion. Its cloud subscription ARR outlook was between $645 million and $655 million, while non-GAAP operating income was pegged at $97 million to $117 million.

Informatica ( INFA ) affirmed its 2024 financial outlook, which included expected revenue of $1.69 billion to $1.71 billion. Analysts polled by Capital IQ are looking for first-quarter and 2024 revenue of $388 million and $1.7 billion, respectively.

"Our business fundamentals continue to be very strong," Chief Executive Amit Walia said Monday. The company is scheduled to release its latest financial results May 1.

Informatica ( INFA ) also said Chief Product Officer Jitesh Ghai was stepping down to explore an executive opportunity at another company.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US telecom agency votes to expand tech crackdown on China
US telecom agency votes to expand tech crackdown on China
Apr 30, 2026
WASHINGTON, April 30 (Reuters) - The Federal Communications Commission on Thursday voted to advance a proposal to bar all Chinese labs from testing electronic devices such as smartphones, cameras and computers for use in the United States. The FCC is also set take an initial vote on Thursday on a separate proposal to bar three major Chinese telecom companies from...
Why Is Crocs Stock Falling Thursday?
Why Is Crocs Stock Falling Thursday?
Apr 30, 2026
Crocs, Inc. ( CROX ) shares traded lower Thursday after the footwear maker reported a mixed first-quarter performance, as strength in its core brand and raised guidance failed to offset weakness in HEYDUDE and margin compression. Earnings Beat Expectations, But Revenue Declines The company posted adjusted earnings of $2.99 per share, topping the analyst consensus estimate of $2.77. Revenue declined...
Ideaya Biosciences Moves Darovasertib Toward FDA Review After Positive Trial Readout
Ideaya Biosciences Moves Darovasertib Toward FDA Review After Positive Trial Readout
Apr 30, 2026
11:08 AM EDT, 04/30/2026 (MT Newswires) -- Ideaya Biosciences ( IDYA ) said the US Food and Drug Administration agreed to review its new drug application for darovasertib in combination with crizotinib for patients with first-line HLA*A2-negative metastatic uveal melanoma under the agency's Oncology Center of Excellence Real-Time Oncology Review program. The phase 2/3 trial of darovasertib in combination with...
--B. Riley Adjusts Universal Technical Institute PT to $49 From $36, Maintains Buy Rating
--B. Riley Adjusts Universal Technical Institute PT to $49 From $36, Maintains Buy Rating
Apr 30, 2026
11:10 AM EDT, 04/30/2026 (MT Newswires) -- Price: 37.75, Change: +1.67, Percent Change: +4.63 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved